MedPath

Lithium carbonate

Generic Name
Lithium carbonate
Brand Names
Carbolith, Lithane, Lithmax, Lithobid
Drug Type
Small Molecule
Chemical Formula
CLi2O3
CAS Number
554-13-2
Unique Ingredient Identifier
2BMD2GNA4V

Overview

Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects.

Background

Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects.

Indication

Lithium carbonate is indicated as a monotherapy for the treatment of acute manic and mixed episodes associated with bipolar 1 disorder in patients ≥7 years of age. It is also indicated as a maintenance treatment for bipolar 1 disorder in patients ≥7 years of age.

Associated Conditions

  • Bipolar 1 Disorder
  • Mixed manic depressive episode
  • Acute Manic episode

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
2024/12/06
Phase 1
Completed
2024/05/22
N/A
Recruiting
Peking University
2023/12/28
Phase 4
Recruiting
Mental Health Services in the Capital Region, Denmark
2023/04/18
Phase 1
Recruiting
First Affiliated Hospital of Chongqing Medical University
2022/06/02
Phase 2
Completed
2022/02/03
Phase 3
Completed
2021/11/18
Phase 3
Recruiting
Negovsky Reanimatology Research Institute
2020/11/10
Phase 3
Active, not recruiting
2020/01/10
Phase 4
Completed
All India Institute of Medical Sciences, Bhubaneswar
2017/06/28
Early Phase 1
UNKNOWN

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
Physicians Total Care, Inc.
54868-1335
ORAL
300 mg in 1 1
4/5/2011
PD-Rx Pharmaceuticals, Inc.
72789-171
ORAL
300 mg in 1 1
11/27/2023
REMEDYREPACK INC.
70518-2312
ORAL
600 mg in 1 1
2/28/2024
Mylan Institutional Inc.
51079-180
ORAL
300 mg in 1 1
12/16/2021
Hikma Pharmaceuticals USA Inc.
0054-0021
ORAL
300 mg in 1 1
10/19/2018
Proficient Rx LP
71205-238
ORAL
300 mg in 1 1
3/1/2019
PD-Rx Pharmaceuticals, Inc.
72789-171
ORAL
300 mg in 1 1
8/23/2023
Hikma Pharmaceuticals USA Inc.
0054-8527
ORAL
300 mg in 1 1
11/22/2022
A-S Medication Solutions
50090-3917
ORAL
300 mg in 1 1
11/24/2022
REMEDYREPACK INC.
70518-1434
ORAL
150 mg in 1 1
2/27/2024

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
Lithium Carbonate Tablets
国药准字H31021756
化学药品
片剂
4/9/2020
Lithium Carbonate Tablets
国药准字H51022980
化学药品
片剂
3/15/2021
Lithium Carbonate Tablets
国药准字H32023154
化学药品
片剂
5/11/2020
Lithium Carbonate Tablets
国药准字H11021410
化学药品
片剂
11/27/2020
Lithium Carbonate Tablets
国药准字H37022538
化学药品
片剂
4/17/2020
Lithium Carbonate Tablets
国药准字H32023287
化学药品
片剂
6/22/2020
Lithium Carbonate Tablets
国药准字H11021443
化学药品
片剂
12/11/2020
Lithium Carbonate Tablets
国药准字H44022320
化学药品
片剂
9/29/2020
Lithium Carbonate Tablets
国药准字H23020224
化学药品
片剂
5/24/2020
Lithium Carbonate Tablets
国药准字H36020271
化学药品
片剂
2/2/2021

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.
© Copyright 2025. All Rights Reserved by MedPath